disabling stroke, or heart failure rehospitalization occurred in 17.6% of the balloon-expandable group and 17.8% of the self-expanding group (HR 1.01; 95% CI 0.71-1.43). The second co-primary endpoint ...
This approval of TNKase marks Genentech’s second approval for stroke, reinforcing the company's long-standing dedication to advancing stroke care as the developer of the only two FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback